Judgment_paragraph 43 · Laboratoires Lyocentre v Lääkealan turvallisuus- ja kehittämiskeskus and Sosiaali- ja terveysalan lupa- ja valvontavirasto (C-109/12)

43In the context of that case-by-case examination, the pharmacological, immunological or metabolic properties of a product constitute the factor on the basis of which it must be ascertained, in the light of the potential capacities of the product, whether it may, for the purposes of Article 1(2)(b) of Directive 2001/83, be used in or administered to human beings with a view to restoring, correcting or modifying physiological functions (BIOS Naturprodukte, paragraph 20).